Legend Biotech Corp income statement

In fiscal 2025, Legend Biotech Corp reported revenue of $1.03bn, up 64.0% on the year before, operating income of −$137m (a -13.3% margin) and net income of −$297m, or −$1.62 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Legend Biotech Corp: income statement, annual
Fiscal year	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	49	60	75	69	117	285	627	1,029
Cost of revenue	—	—	0	0	65	144	216	397
Gross profit	—	—	75	69	52	141	411	632
Research and development	61	162	232	313	336	382	414	415
General and administrative	3	7	23	47	81	107	137	136
Operating income	—	—	—	—	—	−528	−310	−137
Interest expense	0	0	0	1	11	22	2	4
Income before tax	−2	−127	−308	−407	−446	−520	−158	−283
Income tax	1	−26	−42	−4	1	−2	19	14
Net income	−3	−102	−266	−404	−446	−518	−177	−297
Diluted EPS	—	−$1.02	−$2.26	−$2.86	−$2.80	−$2.94	−$0.96	−$1.62
Diluted shares (average)	100m	100m	118m	141m	159m	176m	183m	184m

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: KNSA vs LEGN BBIO vs LEGN BCRX vs LEGN ACAD vs LEGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Legend Biotech Corp's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Legend Biotech Corp.